All News

I talked about chemotherapy and the kindness of nurses who helped me to make those early days of the treatment chair easier: the value of listening, the importance of a smile or touch, the validation of my fears and hopes.

Findings from a long-term analysis of the Women's Intervention Nutrition Study (WINS) show that the deaths of women with hormone receptor–negative breast cancers were reduced by up to 54 percent when they followed a program to reduce their dietary fat intake, which could provide benefit for patients with triple-negative breast cancer.

There is comfort in having a simple cause and effect. The unknown can be difficult to accept.

Debu Tripathy,editor-in-chief of CURE magazine, explains the importance of chemotherapy studies presented at the 2014 San Antonio Breast Cancer Symposium, including new data on the impact of side effects.

Karen Durham never expected to be speaking on behalf of the Metastatic Breast Cancer Alliance

The PD-1 inhibitor Keytruda (pembrolizumab) has demonstrated promising clinical activity with an acceptable safety profile in heavily pretreated patients with recurrent metastatic triple-negative breast cancer (TNBC).

When 34-year-old Jen Levinson was diagnosed with stage 2 breast cancer in 2000, the breast cancer world gained a powerful advocate -- but it wasn't Jen, it was her mother.

Abraxane (nab-paclitaxel) proved markedly more effective than conventional paclitaxel as part of a neoadjuvant regimen for patients with high-risk, early breast cancer, according to results presented at the 2014 San Antonio Breast Cancer Symposium.

The addition of the investigational PI3K inhibitor pictilisib to the aromatase inhibitor Faslodex in patients with metastatic breast cancer yielded some intriguing findings in the FERGI study.

Research presented at the 2014 San Antonio Breast Cancer Symposium shows that high levels of lymphocytes, white blood cells found in the immune system, could help identify women with HER2-positive breast cancer who could forego chemotherapy.

I had forgotten how much I learn during the week of SABCS from oncologists while waiting for the shuttle

Researchers gathered at the annual meeting of the American Society of Hematology to learn about survivorship issues and the late effects their patients encounter years, even decades, after therapy.

Andrea Ivory had an epiphany shortly after being diagnosed with breast cancer in 2004 at age 45.

We all asked why we got breast cancer. Now you can help answer the question.

Three little words that are no less terrifying the second time around.

Treatment with the experimental agent elotuzumab in combination with Revlimid and dexamethasone demonstrated encouraging efficacy in patients with relapsed/refractory multiple myeloma in a phase 1b/2 study.

Tasigna in combination with chemotherapy elicited a complete hematological remissions (CHR) in 87 percent of elderly patients with newly diagnosed Philadelphia-positive acute lymphoblastic leukemia (Ph-positive ALL).

In a first-in-human study, the drug AG-221 generated long-lasting remissions in patients with acute myeloid leukemia (AML).

Zydelig was approved for several recurrent B-cell cancers, and now new data shows the drug also creates a response in older patients newly diagnosed with CLL or SLL.

Following treatment with high-dose chemotherapy and stem cell transplant, patients with relapsed and difficult-to-treat Hodgkin lymphoma who received Adcetris had a higher likelihood of progression-free survival at two years.

Anti-CD38 monoclonal antibodies continue to demonstrate promise across a variety of settings, generating excitement that a new treatment paradigm could be on the horizon for patients with multiple myeloma.

Adding the proteasome inhibitor Kyprolis (carfilzomib) after Revlimid (lenalidomide) in patients with relapsed multiple myeloma showed significant delay of disease progression.

An early study in patients with Hodgkin lymphoma that had progressed on several lines of treatment found that the immunotherapy Keytruda (pembrolizumab) elicited a remarkable response.

At least 80 percent of patients with B-precursor acute lymphoblastic leukemia had a complete minimal residual disease response after a single cycle of treatment with Blincyto (blinatumomab).

Kathleen Vogt is a dynamo when it comes to advocating for her husband Gary, who was diagnosed with a myeloprolifertive neoplasm (MPN) a number of years ago.

The CAR T-cell therapy CTL019 demonstrated an impressive complete response rate in pediatric patients with relapsed/refractory acute lymphoblastic leukemia.

A small phase 1 trial found that certain patients with classical Hodgkin lymphoma (cHL), who had previously failed three or more therapies, responded to the immunotherapy nivolumab.

Caregivers, patient advocates and a clinical researcher were honored at CURE's MPN Heroes event held on Dec. 5 in San Francisco.

The FDA has approved Jakafi (ruxolitinib) as a treatment for patients with polycythemia vera who are resistant or intolerant to hydroxyurea, based on findings from the phase 3 RESPONSE trial.

The FDA approved the anti-CD19 immunotherapy Blincyto (blinatumomab) as a treatment for Philadelphia chromosome-negative acute lymphoblastic leukemia.